U.S. Food and Drug Administration Commissioner Scott Gottlieb during a meeting hosted by the National Health Council Friday stressed the importance of patient-reported outcomes and real-world evidence in the drug review and approval process, according to a MedPage Today report. "If you want these […]
Latest Stories
CVS Caremark to Let Clients Exclude Drugs Based on ICER Assessments
CVS Caremark is set to implement a new strategy that could deliver a blow to drugmakers' pricing power, according to a Fierce Pharma report. The pharmacy benefit manager is planning to let clients cite drug review assessments by the Institute of Clinical and Economic Review to exclude drugs. The […]
PRMA’s Healthcheck Empowers Clients
PRMA Consulting Senior Director Jan McKendrick says the latest version of its Healthcheck late module bolsters client's abilities to optimize payer submission readiness. The digital application, according to a press release, is the result of five years' investment by PRMA Consulting, and "has been […]
Trump White House Applies More Pressure on Pharma to Negotiate with Medicare
The Trump administration this month took another step toward combating high drug prices by requiring drugmakers to negotiate prices for some medications under Medicare's coverage umbrella, according to a Bloomberg report. Health and Human Services Secretary Alex Azar told Bloomberg that private […]
Report Finds Frequently-Prescribed Cardiovascular Drugs Not Aligned with Value
A recent research article published on Health Affairs suggests that frequently-prescribed cardiovascular drugs in the U.S. are not often aligned with their value. The study's authors estimated the cost-effectiveness range for thirty cardiovascular treatments, then pulled evidence from randomized […]
Analysis Reinforces ’15 Study that Found Third of Drug’s List Price Goes Back to Supply Chain
A new analysis published in Health Affairs gives more armor to a 2015 Berkeley Research Group study that found more than one-third of a drug's list price is rebated back to payers, the government, or held by key stakeholders in the supply chain, according to a PhRMA Catalyst report. The analysis by […]
Benchmarking Market Access Strategies for High-Cost Drugs and Biologics
New syndicated report from FirstWord
What is the secret of commercial success for high cost specialty drugs? More specifically, what do the companies that overcome affordability and value demonstration issues do differently? There are lots of strategies that are generating results. This report explores the key issues—and delves into […]
U.K. Wants Price Controls Applied to Biosimilars
The British government is looking to bring biosimilars under the country's statutory price controls starting in 2019. According to a Center for Biosimilars report, the government launched a consultation that details proposed changes to country's price controls. The price controls were reportedly […]
Improving MACRA’s Quality Payment Program, MIPS
Though providers have praised the Centers for Medicare and Medicaid Services (CMS) for MACRA and its Quality Payment Program, there are still some with concerns, according to a RevCycleIntelligence report. Providers, according to the report, are taking issue with the program's two payment systems: […]
Report: Eli Lilly Ignoring California’s Price Hike Notice Law
Eli Lilly is reportedly ignoring a California law which requires drugmakers to both announce and justify prescription drug price hikes months in advance, according to a Los Angeles Times report. The company says it's waiting for a court decision on an industry lawsuit challenging the […]
